Los Angeles Capital Management & Equity Research Inc. bought a new stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 13,890 shares of the company’s stock, valued at approximately $163,000. Los Angeles Capital Management & Equity Research Inc. owned approximately 0.06% of Syndax Pharmaceuticals at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. New York State Common Retirement Fund lifted its position in Syndax Pharmaceuticals by 421.9% during the second quarter. New York State Common Retirement Fund now owns 9,400 shares of the company’s stock worth $131,000 after buying an additional 7,599 shares in the last quarter. Airain ltd purchased a new position in Syndax Pharmaceuticals during the second quarter worth approximately $150,000. Bank of Montreal Can purchased a new position in Syndax Pharmaceuticals during the second quarter worth approximately $158,000. Dimensional Fund Advisors LP purchased a new position in Syndax Pharmaceuticals during the second quarter worth approximately $192,000. Finally, Teachers Advisors LLC lifted its position in Syndax Pharmaceuticals by 109.9% during the second quarter. Teachers Advisors LLC now owns 15,451 shares of the company’s stock worth $216,000 after buying an additional 8,091 shares in the last quarter. Institutional investors and hedge funds own 61.69% of the company’s stock.

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) opened at $8.13 on Wednesday. Syndax Pharmaceuticals, Inc. has a one year low of $6.31 and a one year high of $15.70.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its earnings results on Tuesday, November 7th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.12. The company had revenue of $0.31 million during the quarter, compared to analysts’ expectations of $0.30 million. Syndax Pharmaceuticals had a negative return on equity of 57.90% and a negative net margin of 4,304.34%. The firm’s quarterly revenue was up .0% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.84) earnings per share. equities analysts predict that Syndax Pharmaceuticals, Inc. will post -3.03 EPS for the current year.

A number of brokerages recently commented on SNDX. Instinet reiterated a “buy” rating and set a $22.00 price objective (down previously from $27.00) on shares of Syndax Pharmaceuticals in a research report on Monday, August 14th. Nomura reduced their price objective on Syndax Pharmaceuticals from $27.00 to $22.00 and set a “buy” rating on the stock in a research report on Friday, August 11th. Oppenheimer lifted their price objective on Syndax Pharmaceuticals to $29.00 and gave the stock an “outperform” rating in a research report on Friday, August 11th. Citigroup set a $20.00 price objective on Syndax Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 11th. Finally, Zacks Investment Research downgraded Syndax Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 17th. Two research analysts have rated the stock with a sell rating and eight have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $23.13.

ILLEGAL ACTIVITY WARNING: This story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/12/06/13890-shares-in-syndax-pharmaceuticals-inc-sndx-acquired-by-los-angeles-capital-management-equity-research-inc.html.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.

Institutional Ownership by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Stock Ratings for Syndax Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.